Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.435
+0.035 (1.46%)
Aug 6, 2026, 11:06 AM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $475.85 million as of August 6, 2026. Its market cap has increased by 193.71% in one year.
Market Cap
475.85M
Enterprise Value
298.64M
1-Year Change
193.71%
Ranking
Category
Stock Price
$2.44
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $475.85M, an increase of 373.69%. That is a compound annual growth rate of 31.87%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 6, 2026 | 475.85M | 69.70% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ProKidney | 465.17M |
| Q32 Bio | 459.85M |
| Kyverna Therapeutics | 451.10M |
| Prelude Therapeutics | 438.36M |
| Cabaletta Bio | 436.17M |
| Prothena Corporation | 432.18M |
| Ovid Therapeutics | 429.27M |
| Sagimet Biosciences | 427.32M |